Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant Gram-negative bacteria
Encouraging new data relevant to escalating Gram-negative infection crisis presented at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections, which are increasingly resistant to most available antibiotics, often precipitating the need for clinicians to reach for agents previously reserved for last-line use.
The data, from a pooled analysis of seven clinical trials of patients with either complicated Intra-Abdominal Infections (cIAI) or complicated Urinary Tract Infections (cUTI), demonstrated that ceftazidime-avibactam was effective at treating patients with ceftazidime-resistant Gram-negative pathogens caused by Enterobacteriaceae and Pseudomonas aeruginosa. CAZ-AVI was equally effective at treating patients with ceftazidime-resistant or ceftazidime-susceptible Gram-negative pathogens, regardless of underlying infection. In addition, response rates were similar to carbapenem comparators. Alongside cIAI and cUTI, CAZ-AVI is also being studied for the treatment of Nosocomial Pneumonia including Hospital Acquired Pneumonia and Ventilator Associated Pneumonia.
Hans Sijbesma, Managing Director, Antibiotics Business Unit, AstraZeneca, said: "We are encouraged by the data which highlight the potential for CAZ-AVI to address the challenges of treating patients with life-threatening infections where the lack of effective treatment options has a critical impact on mortality, morbidity and associated healthcare costs."
In Europe, it is estimated that Gram-negative bacteria are responsible for two thirds of the 25,000 deaths resulting from antimicrobial resistance reported annually. Resistance to carbapenems is particularly troubling as they are one of the last lines of defence in severe hospital-treated Gram-negative infections.
In addition to the CAZ-AVI data being presented at this year's ECCMID, there are also five abstracts featuring new Zinforo (ceftaroline fosamil) data, an antibiotic approved for the treatment of adult patients with complicated skin and soft tissue infections (cSSTI) or community-acquired pneumonia (CAP), as well as two abstracts for ATM-AVI, an investigational antibiotic being developed for the treatment of targeted serious bacterial infections. CAZ-AVI, Zinforo and ATM-AVI are key antibiotics within AstraZeneca's recently established Antibiotic Business Unit.
CAZ-AVI combines a cephalosporin (ceftazidime) with a next generation non-beta lactam beta-lactamase inhibitor (avibactam). The addition of avibactam protects ceftazidime from being broken down by beta-lactamases that are produced by these resistant bacteria. It is being developed to treat a broad range of Gram-negative bacterial infections which are becoming increasingly resistant to antibiotics and pose a threat to public health, including multi-drug resistant P. aeruginosa, carbapenem-resistant Gram-negative pathogens, & ESBL-producing Enterobacteriaceae.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance